Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (579)	8/27/2000 11:42:13 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3044

There are many reasons to own the stock, at a reasonable valuation, apart from obesity. I do not currently hold any shares. $12.3 billion. Amazing performance.

To: LLCF who wrote (579)	8/28/2000 9:09:40 AM
From: rkrw	Read Replies (1) \| Respond to of 3044

<<<I'm seriously considering punting the balance of my MLNM on this rally based on their stated indication of choice being obesity. Despite the huge potential indication I can't imagine a drug being developed to counter a problem that has developed in the past few decades due to lack of exercise, intake of 'crap', and or environmental poisons... assuming the 'obesity quest' of MLNM being a bust, any reason to own the stock anyone?>>> This is precisely the societal bias that mlnm mentions in presentations, the broad belief that obesity equals laziness. They believe in a genetic link to obesity and probably have the pharmaceutical industries largest effort in the area. I assume you don't really believe that mlnm is a one-product or one-therapeutic category biotech. imo, mlnm has the best mgt in biotech, the best platform in biotech-broad, highly flexible, constantly evolving, the smartest collection of scientists in biotech. This is one smart company. I've sold roughly half my initial position this year. I don't plan on selling my remaining shares. As a rational person its difficult to justify a $12B market cap today, but when Mark Levin says the goal is to be the next Merck or Pfizer, I tend to believe him.